Answers are grounded in this paper and cite their sources.
shRNA-based genetic constructs, delivered to cells by AAV, have been developed as a potential gene therapy treatment for GNAO1 encephalopathy.
No takes yet. Share an insight, caveat, or question.
Lunev et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: